Completed × Has results × Lymphoma, T-Cell, Peripheral × Clear all A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Phase 2 Completed
82 enrolled 13 charts
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Phase 2 Completed
82 enrolled 20 charts
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Phase 1 Completed
26 enrolled 24 charts
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Phase 1/2 Completed
142 enrolled 30 charts
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Phase 1/2 Completed
171 enrolled 23 charts
PRIMO
Phase 2 Completed
156 enrolled 21 charts
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
Phase 2 Completed
6 enrolled 11 charts
REDIRECT
Phase 2 Completed
108 enrolled 24 charts
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
Phase 1/2 Completed
18 enrolled 14 charts
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Phase 2 Completed
77 enrolled 20 charts
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
Completed
95 enrolled 30 charts
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 2 Completed
55 enrolled 18 charts
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
Phase 2 Completed
52 enrolled 24 charts
PTCL
Phase 2 Completed
65 enrolled 16 charts
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Phase 2 Completed
131 enrolled 28 charts
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
Phase 1/2 Completed
42 enrolled 13 charts
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Phase 2 Completed
1 enrolled 5 charts
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Phase 2 Completed
4 enrolled 11 charts
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 2 Completed
67 enrolled 13 charts
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
Phase 2 Completed
76 enrolled 10 charts
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Phase 2 Completed
34 enrolled 12 charts
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Phase 2 Completed
21 enrolled 11 charts
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Phase 1 Completed
16 enrolled 16 charts
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
Phase 2 Completed
46 enrolled 7 charts
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1/2 Completed
50 enrolled 15 charts
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Phase 1 Completed
286 enrolled 26 charts
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Phase 1 Completed
26 enrolled 19 charts
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 2 Completed
41 enrolled 8 charts
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
Phase 1 Completed
11 enrolled 16 charts
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Phase 1 Completed
15 enrolled 18 charts
PTCL
Phase 2 Completed
129 enrolled 12 charts
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
Phase 2 Completed
45 enrolled 28 charts
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Phase NA Completed
174 enrolled 17 charts
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Phase 2 Completed
60 enrolled 8 charts
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Phase 1/2 Completed
58 enrolled 12 charts
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Phase 2 Completed
49 enrolled 11 charts
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Phase 2 Completed
131 enrolled 16 charts
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Phase 2 Completed
60 enrolled 10 charts
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
150 enrolled 14 charts
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Phase 1 Completed
58 enrolled 15 charts
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Phase 1/2 Completed
119 enrolled 13 charts
PROPEL
Phase 2 Completed
115 enrolled 11 charts
FIL_GEMRO
Phase 2 Completed
20 enrolled 11 charts
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Phase 3 Completed
85 enrolled 26 charts
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
94 enrolled 11 charts
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
77 enrolled 12 charts
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1/2 Completed
51 enrolled 34 charts
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Phase 1 Completed
13 enrolled 18 charts
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
Phase 2 Completed
16 enrolled 10 charts
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Phase 3 Completed
271 enrolled 25 charts